Vera Therapeutics names Nancy Boman as chief regulatory officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
July 9, 2026 8:00 AM EDTBRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer position. William Turner, current Chief Regulatory Officer of Vera Therapeutics, is planning to retire and transition to the role of Strategic Advisor in the third quarter of this year after a successful tenure at the company, including the recent accelerated approval of Vera Therapeutics first therapy in IgA nephropathy (IgAN), TRUTAKNAÂ (atacicept-vymj). Nancy Boman, M.D., Ph.D., will succeed Mr. Turner as Chief Regulatory... More
